12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avandia rosiglitazone: Phase III data

Researchers at George Washington University and colleagues reported data from the double-blind, U.S. Phase III TODAY trial in 699 Type II diabetics aged 10-17 showing that twice-daily Avandia plus metformin met the primary endpoint of a lower rate of treatment failure, defined as loss of glycemic control, vs....

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >